LDL-C
Showing 1 - 25 of >10,000
Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol Trial (Achieving a Target LDL-C level of 25mg/dL=
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
- Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL
- Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL
- (no location specified)
Mar 14, 2023
To Reduce the LDL-C Level in Hypercholesteremia Patients Trial (RN0191)
Not yet recruiting
- To Reduce the LDL-C Level in Hypercholesteremia Patients
- (no location specified)
Nov 13, 2023
Cholesterol Variability, Trained Immunity Trial (Atorvastatin)
Not yet recruiting
- Cholesterol Variability
- Trained Immunity
- (no location specified)
Mar 17, 2023
Categories and Attaining LDL-C Targets in Middle Eastern Adults
Not yet recruiting
- Atherosclerotic Cardiovascular Risk
- Low-density-lipoprotein (LDL) Cholesterol
- (no location specified)
Feb 16, 2023
Diet-induced Elevations in LDL-C and Progression of
Recruiting
- Hypercholesterolemia
-
Torrance, CaliforniaLundquist Institute for Biomedical Innovation at Harbor UCLA Med
Feb 17, 2023
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other
Not yet recruiting
- To Reduce the LDL-C Level in Hypercholesteremia Adult Patients
- Combination for Subgroup High LDL-c Patients With Other Comorbidities
- RN0191 INJECTION
- (no location specified)
Jun 14, 2023
Cardiovascular Diseases, Hyper-LDL-cholesterolemia Trial in Cincinnati (lerodalcibep)
Active, not recruiting
- Cardiovascular Diseases
- Hyper-LDL-cholesterolemia
-
Cincinnati, Ohio
- +2 more
Nov 3, 2022
Cardiovascular Diseases Trial (Meal timing)
Recruiting
- Cardiovascular Diseases
- Meal timing
-
Bath, United KingdomDepartment for Health, University of Bath
Oct 10, 2022
Coronary Artery Disease Progression Trial (Intensive lipid-lowering control, Moderate-intensity lipid-lowering control)
Not yet recruiting
- Coronary Artery Disease Progression
- Intensive lipid-lowering control
- Moderate-intensity lipid-lowering control
- (no location specified)
Jul 13, 2022
Cardiovascular Risk Factor Trial in Stanford (Plant Sterol)
Completed
- Cardiovascular Risk Factor
- Plant Sterol
-
Stanford, CaliforniaStanford University
Mar 31, 2022
Hypercholesterolemia Trial (MK0653, ezetimibe / Duration of Treatment: 4 Weeks)
Completed
- Hypercholesterolemia
- MK0653, ezetimibe / Duration of Treatment: 4 Weeks
- (no location specified)
Feb 7, 2022
Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke Trial in India, Israel, United States (lerodalcibep,
Active, not recruiting
- Cardiovascular Risk Factor
- +3 more
- lerodalcibep
- Placebo
-
Cincinnati, Ohio
- +5 more
Nov 3, 2022
Heterozygous Familial Hypercholesterolemia Trial in Worldwide (lerodalcibep)
Active, not recruiting
- Heterozygous Familial Hypercholesterolemia
-
Cincinnati, Ohio
- +6 more
Nov 3, 2022
Dyslipidemia, Hypercholesterolemia Trial in Seoul (Test Meal)
Completed
- Dyslipidemia
- Hypercholesterolemia
- Test Meal
-
Seoul, Korea, Republic ofMSD Korea Ltd.
Feb 7, 2022
Hyperlipemia Trial in Beijing (RBD7022, Placebo)
Recruiting
- Hyperlipemia
- RBD7022
- Placebo
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jun 12, 2023
Hypercholesterolemia Trial (ezetimibe (+) simvastatin, Comparator: atorvastatin, Comparator: rosuvastatin)
Completed
- Hypercholesterolemia
- ezetimibe (+) simvastatin
- +2 more
- (no location specified)
Feb 7, 2022
Familial Hypercholesterolemia Trial in Odense C (Biochemistry interpretive comment on elevated LDL-C levels)
Not yet recruiting
- Familial Hypercholesterolemia
- Biochemistry interpretive comment on elevated LDL-C levels
-
Odense C, DenmarkDepartement of Cardiology, Odense University Hospital
Nov 10, 2022
Hyperlipidemia Trial in Changsha, Chengdu, Beijing (100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg
Completed
- Hyperlipidemia
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
- +2 more
-
Changsha, Hunan, China
- +2 more
Dec 2, 2021
Non-alcoholic Steatohepatitis (NASH) Trial in Las Vegas (ECC4703, Placebo)
Recruiting
- Non-alcoholic Steatohepatitis (NASH)
- ECC4703
- Placebo
-
Las Vegas, NevadaEccogene Investigational Site
Sep 20, 2022
Hyperlipidemia Trial in Leuven (Cholesfytol NG®) supplement)
Completed
- Hyperlipidemia
- Cholesfytol NG®) supplement
-
Leuven, BelgiumCliniques universitaires St-Luc and Institut de Recherche Expéri
Aug 18, 2023
Acute Coronary Syndrome Trial (Repatha or Praluent)
Not yet recruiting
- Acute Coronary Syndrome
- Repatha or Praluent
- (no location specified)
Sep 13, 2021
sessmenT and treAtment In AustraliaN Primary Care
Not yet recruiting
- Atherosclerotic Cardiovascular Disease (ASCVD)
- +3 more
- Inclisiran Prefilled Syringe
-
Clayton, Victoria, AustraliaMonash Health
Apr 17, 2023